series-c-plus
Stage
1
Investors
About
ProQR develops RNA therapies using its proprietary Axiomer® RNA editing technology to treat genetic disorders and rare diseases.
Explore ProQR's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.